Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $139.00.

The personalized cancer vaccine market is gaining rapid momentum, driven by biotech advancements and rising demand for targeted immunotherapies. The new 2025 report analyzes key players like BioNTech, ...

BioNTech has passed on Autolus Therapeutics’ dual targeting CAR-T cell therapy. One year after securing a chance to co-develop the prospect, BioNTech let the option expire as part of its ...

My young patient cheerfully jumped down from the exam table following a routine checkup and reached for his mother’s hand. Then I asked if we could proceed with a vaccine that was recommended at his ...

As various biotechs across the world specialize in the production of cancer vaccines for different indications, with the major players being multinational companies like Biontech, CureVac, and Moderna ...

BioNTech is expanding its oncology pipeline with FixVac, iNeST, and BNT327 for individualized cancer treatments. However, note that some regulatory and legal challenges, including a Moderna patent ...

The NIH is funding at least 130 studies involving the mRNA technology in covid vaccines produced by Pfizer-BioNTech and Moderna that have been administered to billions of people worldwide.

Lymes' Senior Center's $6.4 million upgrade set for March 19 completion ...

MLB, Topps and Nike have partnered to recognize baseball's elite performers from last season with custom gold-embellished MLB logos on their jerseys that will then be used to create trading cards.

Meta is being sued by three French publishers and author groups for using their copyrighted works without permission to train AI models, although they might have had a stronger case if they waited ...

BioNTech SE (NASDAQ:BNTX) just released its full-year report and things are looking bullish. Results overall were credible, with revenues arriving 3.9% better than analyst forecasts at €2.8b ...